- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05269966
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
A Real-world, Prospective, Multi-center, Open-label, Phase IV Clinical Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Study Overview
Status
Intervention / Treatment
Detailed Description
The study was a prospective, multi-center, open-label, interventional phase IV clinical study.
The study treatment, i.e., brolucizumab was prescribed in terms of the marketing authorization; the assignment of the patient to the therapy was decided within the current practice and the medical indication. It was clearly separated from the decision to include the patient in the study.
All patients with Neovascular Age-related Macular Degeneration (nAMD) who were planned to be treated with brolucizumab and had provided informed consent were enrolled in the study. A total of 12 sites in India were evaluated for the study conduct. This is to note that site #03 was not selected, and site #07 was not initiated, and patients were enrolled in the study only from 10 sites.
The treatment period for each patient was 56 weeks after the start of brolucizumab treatment.
Study visits were scheduled at Week 4, Week 8, Week 16, and thereafter at intervals of 8 weeks or 12 weeks after disease activity assessment at Week 16. If the investigators required more frequent follow-up visits, it was done according to their discretion and clinical judgment. Any patient who suffered from IOI during the study period was not re-challenged with brolucizumab.
The study population consisted of adult male and female outpatients aged 50 years and above, diagnosed with nAMD for whom the treating the physician (Investigator) had prescribed treatment with brolucizumab 6 mg injection in adherence with the local Summary of Product Characteristics (SmPC) or Prescribing Information (PI).
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Chandigarh, India, 160012
- Novartis Investigative Site
-
New Delhi, India, 110029
- Novartis Investigative Site
-
-
Ahmedabad
-
Asarwa, Ahmedabad, India, 380016
- Novartis Investigative Site
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380052
- Novartis Investigative Site
-
-
Karnataka
-
Bangalore, Karnataka, India, 560 010
- Novartis Investigative Site
-
-
Tamilnadu
-
Chennai, Tamilnadu, India, 600018
- Novartis Investigative Site
-
-
Telangana
-
Hyderabad, Telangana, India, 500034
- Novartis Investigative Site
-
-
Uttar Pradesh
-
Varanasi, Uttar Pradesh, India, 221010
- Novartis Investigative Site
-
-
West Bengal
-
Hooghly, West Bengal, India, 712223
- Novartis Investigative Site
-
Kolkatta, West Bengal, India, 700 073
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female or male, treatment naïve patient with ≥50 years of age, with neovascular age-related macular degeneration (nAMD).
- Patient or legally acceptable representative (LAR) willing to voluntarily provide signed informed consent for participation in the study.
Note: In case where both eyes are affected, data of only one eye ['study eye'] will be recorded. Selection of the eye to be considered for the purpose of the study [referred to as 'study eye'] will be as per the Investigator's discretion.
Exclusion Criteria:
- Patients fulfilling any of the following criteria are not eligible for this study:
- Patient having other eye diseases that could compromise the VA.
- Patient with existing or suspected ocular or periocular infection in the study eye.
- Patient with an existing intraocular inflammation (IOI).
- Patient with uncontrolled glaucoma defined as intraocular pressure > 25 mmHg despite treatment with anti-glaucoma medication, or according to Investigator's judgment.
- Patient who has undergone intraocular surgery within 3 months prior to enrollment in this study.
- Patient having scar, fibrosis and atrophy involving the center of the fovea in the study eye.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Brolucizumab
Brolucizumab, formerly known as ESBA1008, is a humanized single-chain Fv (scFv) antibody fragment. Brolucizumab 6 mg was administered by Intravitreal (IVT) injections as per the Prescribing information (PI) and in line with the treating physician's clinical judgement. Patients received loading doses of brolucizumab at Day 0/Visit 1, Week 4/Visit 2 and Week 8/Visit 3. After the loading doses, at Week 16, disease activity assessment (DAA) was performed based on Best Corrected Visual Acuity (BCVA) and Optical Coherence Tomography (OCT) to assess whether the patient required q8w or q12w dosing. |
Single-chain antibody fragment (scFv) Brolucizumab 6 mg was administered by Intravitreal (IVT) injection as per the Prescribing information (PI) and in line with the treating physician's clinical judgement. Patients received loading doses of brolucizumab at Day 0/Visit 1, Week 4/Visit 2 and Week 8/Visit 3. After the loading doses, at Week 16, disease activity assessment (DAA) were performed based on Best Corrected Visual Acuity (BCVA) and Optical Coherence Tomography (OCT) to assess whether the patient required q8w or q12w dosing.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and characteristics of treatment-emergent adverse events during the 56 weeks of treatment with brolucizumab.
Time Frame: Week 56
|
To evaluate ocular & non-ocular safety of intravitreal brolucizumab in real-world patients with nAMD.
|
Week 56
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change in BCVA from baseline to week 16 and week 56 as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letters.
Time Frame: Week 56
|
To evaluate the effectiveness of brolucizumab in the management of nAMD in terms of change in best-corrected visual acuity (BCVA) from baseline to Week 56.
|
Week 56
|
Percentage (%) of patient eyes with gain in BCVA of 15/10/5 ETDRS letters or more from baseline to week 16 and week 56.
Time Frame: Week 56
|
To evaluate the effectiveness of brolucizumab in the management of nAMD in terms of change in best-corrected visual acuity (BCVA) from baseline to Week 56.
|
Week 56
|
Percentage (%) of patient eyes with loss in BCVA of 15/10/5 ETDRS letters or more from baseline to week 16 and week 56.
Time Frame: Week 56
|
To evaluate the effectiveness of brolucizumab in the management of nAMD in terms of change in best-corrected visual acuity (BCVA) from baseline to Week 56.
|
Week 56
|
Number of anti-VEGF injections, during the 56 weeks of treatment with brolucizumab.
Time Frame: Week 56
|
Characterize the number of anti-VEGF injections during the 56 weeks of treatment with brolucizumab.
|
Week 56
|
Number of Non-injection visits during the 56 weeks of treatment with brolucizumab.
Time Frame: 56 Weeks
|
Characterize number of non-injection visits during the 56 weeks of treatment with brolucizumab.
|
56 Weeks
|
Total number of visits during the 56 weeks of treatment with brolucizumab.
Time Frame: 56 Weeks
|
Characterize the total number of visits during the 56 weeks of treatment with brolucizumab.
|
56 Weeks
|
Percentage (%) of patient eyes with at least one duration of interval between injections ≥ 8 weeks but <12 weeks.
Time Frame: Week 56
|
Estimate the percentage (%) of patient eyes with anti-VEGF injection intervals q8w and q12w during the 56 weeks of treatment with brolucizumab.
|
Week 56
|
Percentage (%) of patient eyes with at least one duration of interval between injections ≥ 12 weeks.
Time Frame: Week 56
|
Estimate the percentage (%) of patient eyes with anti-VEGF injection intervals q8w and q12w during the 56 weeks of treatment with brolucizumab.
|
Week 56
|
Absence of intra-retinal fluid from baseline to week 16 and week 56.
Time Frame: Week 56
|
Estimate effect of brolucizumab on fluid (increased/reduced/unchanged) from baseline to week 16 and week 56 based on Optical Coherence Tomography Image Analysis.
|
Week 56
|
Absence of sub-retinal fluid from baseline to week 16 and week 56.
Time Frame: Week 56
|
Estimate effect of brolucizumab on fluid from baseline to week 16 and week 56.
|
Week 56
|
Estimate CST change from baseline to week 16 and at week 56.
Time Frame: Week 56
|
Estimate effect of brolucizumab on central subfield thickness (CST) from baseline to week 16 and week 56 as measured by Optical Coherence Tomography (in µm)
|
Week 56
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publications and helpful links
General Publications
- Rein DB, Wittenborn JS, Zhang X, Honeycutt AA, Lesesne SB, Saaddine J; Vision Health Cost-Effectiveness Study Group. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol. 2009 Apr;127(4):533-40. doi: 10.1001/archophthalmol.2009.58.
- Kawasaki R, Yasuda M, Song SJ, Chen SJ, Jonas JB, Wang JJ, Mitchell P, Wong TY. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology. 2010 May;117(5):921-7. doi: 10.1016/j.ophtha.2009.10.007. Epub 2010 Jan 27.
- Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE, Hofman A, Jensen S, Wang JJ, de Jong PT. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology. 2001 Apr;108(4):697-704. doi: 10.1016/s0161-6420(00)00580-7.
- Miller JW. Age-related macular degeneration revisited--piecing the puzzle: the LXIX Edward Jackson memorial lecture. Am J Ophthalmol. 2013 Jan;155(1):1-35.e13. doi: 10.1016/j.ajo.2012.10.018. Erratum In: Am J Ophthalmol. 2018 Nov;195:249.
- Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984 Nov;102(11):1640-2. doi: 10.1001/archopht.1984.01040031330019.
- Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012 May 5;379(9827):1728-38. doi: 10.1016/S0140-6736(12)60282-7.
- Shah AR, Del Priore LV. Progressive visual loss in subfoveal exudation in age-related macular degeneration: a meta-analysis using Lineweaver-Burke plots. Am J Ophthalmol. 2007 Jan;143(1):83-89. doi: 10.1016/j.ajo.2006.09.043. Epub 2006 Oct 20.
- Shah AR, Del Priore LV. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration. Ophthalmology. 2009 Oct;116(10):1901-7. doi: 10.1016/j.ophtha.2009.03.055. Epub 2009 Jul 9.
- Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, Ma C, Menchini U, Miller J, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Strong HA, Stur M, Su XY, Virgili G; Treatment of Age-related Macular Degeneration with Photodynamic Therapy study group; Verteporfin in Photodynamic Therapy study group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003 Sep;136(3):407-18. doi: 10.1016/s0002-9394(03)00223-x.
- Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt JC, Martone JF, Royall RM, Witt KA, Ezrine S. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med. 1991 Nov 14;325(20):1412-7. doi: 10.1056/NEJM199111143252004.
- Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008 Jan;115(1):116-26. doi: 10.1016/j.ophtha.2007.03.008. Epub 2007 Aug 6. Erratum In: Ophthalmology. 2008 Sep;115(9):1524. Wong, Tien [corrected to Wong, Tien Y].
- Menrad A, Anderer FA. Expression of LDL receptor on tumor cells induced by growth factors. Anticancer Res. 1991 Jan-Feb;11(1):385-90.
- Campbell JP, Bressler SB, Bressler NM. Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration. Arch Ophthalmol. 2012 Jun;130(6):794-5. doi: 10.1001/archophthalmol.2011.2480. No abstract available.
- Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010. Am J Ophthalmol. 2012 Feb;153(2):209-213.e2. doi: 10.1016/j.ajo.2011.10.016.
- Nguyen QD, Das A, Do DV, Dugel PU, Gomes A, Holz FG, Koh A, Pan CK, Sepah YJ, Patel N, MacLeod H, Maurer P. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020 Jul;127(7):963-976. doi: 10.1016/j.ophtha.2019.12.031. Epub 2020 Jan 17.
- Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG; HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020 Jan;127(1):72-84. doi: 10.1016/j.ophtha.2019.04.017. Epub 2019 Apr 12.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- AMD
- Macular degeneration
- neovascular age-related macular degeneration
- vision loss
- retinal vein occlusion
- RVO
- wet macular degeneration
- age-related macular degeneration (ARMD)
- macula damage
- retina damage
- dry macular degeneration
- nAMD
- Subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRTH258AIN01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neovascular Age-related Macular Degeneration (nAMD)
-
AbbVieAbbVieEnrolling by invitationGene Therapy | AMD | nAMD | Wet AMD | Neovascular Age-Related Macular Degeneration (nAMD) | wAMDUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
AsclepiX Therapeutics, Inc.TerminatedNeovascular Age-Related Macular Degeneration (nAMD)United States
-
Ocugenix CorporationNot yet recruitingNeovascular Age-related Macular Degeneration (nAMD)United States
-
Aerie PharmaceuticalsAlcon ResearchRecruitingNeovascular Age-related Macular Degeneration (nAMD)United States
-
SandozCompletedNeovascular Age-related Macular Degeneration (nAMD)United States
-
Kyowa Kirin, Inc.RecruitingNeovascular Age-Related Macular Degeneration (nAMD)United States, Japan, Korea, Republic of, Australia
-
Hoffmann-La RocheRecruitingNeovascular Age-related Macular Degeneration (nAMD)Belgium, Korea, Republic of, Germany, Spain, United Kingdom, Australia, Italy, Argentina, Israel, Austria, Brazil, France, Singapore, Switzerland, Taiwan, Turkey
-
Novartis PharmaceuticalsActive, not recruitingNeovascular Age-related Macular Degeneration (nAMD)Portugal
-
SandozCompletedNeovascular Age-related Macular Degeneration (nAMD)United States
Clinical Trials on Injection Brolucizumab
-
Yeungnam University College of MedicineNovartisNot yet recruitingAge-Related Macular Degeneration | Pachychoroid Neovasculopathy
-
Benha UniversityRecruiting
-
Novartis PharmaceuticalsRecruitingNeovascular Age-related Macular DegenerationUnited Arab Emirates
-
Novartis PharmaceuticalsWithdrawn
-
Novartis PharmaceuticalsNot yet recruiting
-
Novartis PharmaceuticalsTerminatedNeovascular Age-related Macular DegenerationUnited Kingdom
-
Novartis PharmaceuticalsActive, not recruitingNeovascular Age-related Macular Degeneration (nAMD)Portugal
-
Novartis PharmaceuticalsActive, not recruitingDiabetic Macular Edema (DME) | Neovascular Age-related Macular Degeneration (nAMD)Germany
-
Novartis PharmaceuticalsCompletedNeovascular Age-related Macular DegenerationJapan
-
Vista KlinikNovartisTerminatedNeovascular Age-related Macular DegenerationSwitzerland